BeOne Medicines (BEIGF) Total Current Liabilities (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Total Current Liabilities data on file, last reported at $1.8 billion in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $1.8 billion, down 8.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 billion (down 8.68% YoY), and the FY2025 annual result was $1.8 billion, down 17.43% from the prior year.
• Total Current Liabilities declined to $1.8 billion in Q1 2026 per BEIGF's latest filing, from $1.8 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $2.4 billion in Q3 2025 and troughed at $917.4 million in Q4 2022.
• A 5-year average of $1.7 billion and a median of $1.8 billion in 2026 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities slumped 42.65% in 2022, then jumped 97.32% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $917.4 million in 2022, then jumped by 97.32% to $1.8 billion in 2023, then advanced by 22.36% to $2.2 billion in 2024, then dropped by 17.43% to $1.8 billion in 2025, then decreased by 0.95% to $1.8 billion in 2026.
• Business Quant data shows BEIGF's Total Current Liabilities at $1.8 billion in Q1 2026, $1.8 billion in Q4 2025, and $2.4 billion in Q3 2025.